# Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum

> **NCT05512676** · — · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 40 (actual)

## Conditions studied

- Ovarian Neoplasm
- Chemotherapeutic Toxicity
- Chemotherapy Effect
- Chemotherapy-induced Neutropenia
- Chemotherapy-induced Nausea and Vomiting

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05512676
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-07
- **Primary completion:** 2019-05-20
- **Final completion:** 2022-08-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512676, "Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05512676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*